219 related articles for article (PubMed ID: 32627003)
1. Molecular mechanism of gossypol mediating CCL2 and IL‑8 attenuation in triple‑negative breast cancer cells.
Messeha SS; Zarmouh NO; Mendonca P; Cotton C; Soliman KFA
Mol Med Rep; 2020 Aug; 22(2):1213-1226. PubMed ID: 32627003
[TBL] [Abstract][Full Text] [Related]
2. Effects of gossypol on apoptosis‑related gene expression in racially distinct triple‑negative breast cancer cells.
Messeha SS; Zarmouh NO; Mendonca P; Alwagdani H; Cotton C; Soliman KFA
Oncol Rep; 2019 Aug; 42(2):467-478. PubMed ID: 31173249
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells.
Messeha SS; Zarmouh NO; Mendonca P; Alwagdani H; Kolta MG; Soliman KFA
PLoS One; 2018; 13(7):e0201116. PubMed ID: 30059519
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effects of butein on cell proliferation and TNF-α-induced CCL2 release in racially different triple negative breast cancer cells.
Mendonca P; Horton A; Bauer D; Messeha S; Soliman KFA
PLoS One; 2019; 14(10):e0215269. PubMed ID: 31665136
[TBL] [Abstract][Full Text] [Related]
5. Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Antonie L; Soliman KFA
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955463
[TBL] [Abstract][Full Text] [Related]
6. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
[TBL] [Abstract][Full Text] [Related]
7. Diallyl disulfide inhibits TNFα-induced CCL2 release by MDA-MB-231 cells.
Bauer D; Mazzio E; Soliman KF; Taka E; Oriaku E; Womble T; Darling-Reed S
Anticancer Res; 2014 Jun; 34(6):2763-70. PubMed ID: 24922637
[TBL] [Abstract][Full Text] [Related]
8. Sericin inhibits MDA‑MB‑468 cell proliferation via the PI3K/Akt pathway in triple‑negative breast cancer.
Niu L; Yang S; Zhao X; Liu X; Si L; Wei M; Liu L; Cheng L; Qiao Y; Chen Z
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313947
[TBL] [Abstract][Full Text] [Related]
9. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
10. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
[TBL] [Abstract][Full Text] [Related]
11. Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells.
Noori MS; O'Brien JD; Champa ZJ; Deosarkar SP; Lanier OL; Qi C; Burdick MM; Schwartz FL; Bergmeier SC; McCall KD; Goetz DJ
Eur J Pharmacol; 2017 May; 803():130-137. PubMed ID: 28343970
[TBL] [Abstract][Full Text] [Related]
12. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
14. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
15. Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells.
You D; Jeong Y; Yoon SY; A Kim S; Kim SW; Nam SJ; Lee JE; Kim S
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846813
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase‑type plasminogen activator.
Jin H; Choi H; Kim ES; Lee HH; Cho H; Moon A
Oncol Rep; 2021 Jan; 45(1):299-308. PubMed ID: 33155661
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
18. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
[TBL] [Abstract][Full Text] [Related]
19. KLF15 suppresses tumor growth and metastasis in Triple-Negative Breast Cancer by downregulating CCL2 and CCL7.
Kanyomse Q; Le X; Tang J; Dai F; Mobet Y; Chen C; Cheng Z; Deng C; Ning Y; Yu R; Zeng X; Xiang T
Sci Rep; 2022 Nov; 12(1):19026. PubMed ID: 36347994
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.
Wu J; Sun Z; Sun H; Li Y
Mol Med Rep; 2018 Jan; 17(1):562-570. PubMed ID: 29115608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
